Rituximab Treatment of Graves' Dysthyroid Ophthalmopathy
Part of paid clinical trials in Oakland, California.
- Sponsor
- Silkiss, Rona Z., M.D., FACS
- Study ID
- NCT00424151
- Phase
- PHASE1/PHASE2
- Status
- Completed
Conditions
- Graves' Dysthyroid Ophthalmopathy
- Thyroid Related Orbitopathy
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Rituximab — DRUG
Study Details
This study is designed to treat patients with Graves' disease with Rituximab in an attempt to prevent or reverse the physically deforming and debilitating consequences of this disease.
Key Dates
- Start date
- Dec 31, 2006
- Status verified
- Oct 2010
- Primary completion
- Mar 31, 2009
- Completion
- Mar 31, 2009
Study Design
- Enrollment
- 12 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Primary Outcome Measure
Clinical response to treatment, alteration in immunoglobulin levels [ Time Frame: One year post infusion ]
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Rona Z. Silkiss, MD, FACS | Oakland | California | 94609 | - |
| Simeon A. Lauer, MD | New York | New York | 10021 | - |